Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sarmal is a private U.S. genomics company developing platform technologies for DNA sequencing and nucleic acid detection. Its lead technologies are the FLASH Sequencing Platform, a single-molecule sequencing approach aimed at very long read lengths and low-cost whole-genome sequencing, and the TEEM Target Detection Platform, a rapid field-deployable nucleic acid diagnostic system. The company positions its products around making genetic analysis and molecular testing faster, more accessible, and more affordable. Sarmal appears to operate as a platform and tools company rather than a therapeutic drug developer, with a focus on research, diagnostics, and preventive health applications. The business is based in the San Diego/La Jolla area and has disclosed venture backing and recent financing activity.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Sarmal.